Ophthalmology

1-16 of 79

• 

  RestartResume

  Ischemic vs. Non-Ischemic RVO: How Do You Know?

  RestartResume

  Ischemic vs. Non-Ischemic RVO: How Do You Know?

  Eye on Ocular Health

  Ischemic vs. Non-Ischemic RVO: How Do You Know?

  Jessica Randolph, MD

  • 

    

    Jessica Randolph, MD

• 

  RestartResume

  Retinal Vein Occlusion in Younger Patients: Key Care Considerations

  RestartResume

  Retinal Vein Occlusion in Younger Patients: Key Care Considerations

  Eye on Ocular Health

  Retinal Vein Occlusion in Younger Patients: Key Care Considerations

  Jessica Randolph, MD

  • 

    

    Jessica Randolph, MD

• 

  RestartResume

  Retinal Vein Occlusion as a Marker of Systemic Risk

  RestartResume

  Retinal Vein Occlusion as a Marker of Systemic Risk

  Eye on Ocular Health

  Retinal Vein Occlusion as a Marker of Systemic Risk

  Ashkan Abbey, MD

  • 

    

    Ashkan Abbey, MD

• 

  RestartResume

  Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments

  RestartResume

  Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments

  CME/CE Broadcast Replay

  Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments

  Prem S. Subramanian, MD, PhD; Andrew G. Lee, MD

  1.00 credit

  • 

    

    Prem S. Subramanian, MD, PhD

  • 

    

    Andrew G. Lee, MD

  • 

    

    Valerie Biousse, MD

  1.00 credit

• 

  RestartResume

  Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR

  RestartResume

  Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR

  Ophthalmology

  Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR

  Jordan Deaner; Vaidehi S. Dedania, MD

  • 

    

    Jordan Deaner

  • 

    

    Vaidehi S. Dedania, MD

  • 

    

    Rehan M. Hussain, MD

• 

  RestartResume

  Trends in PDR Treatments

  RestartResume

  Trends in PDR Treatments

  Ophthalmology

  Trends in PDR Treatments

  Maria H. Berrocal, MD; Katharine Talcott, MD

  • 

    

    Maria H. Berrocal, MD

  • 

    

    Katharine Talcott, MD

• 

  RestartResume

  Logistical Considerations with Anti-VEGF Treatment in Wet AMD

  RestartResume

  Logistical Considerations with Anti-VEGF Treatment in Wet AMD

  Eye on Ocular Health

  Logistical Considerations with Anti-VEGF Treatment in Wet AMD

• 

  RestartResume

  GLP-1 Use and AMD Risk

  RestartResume

  GLP-1 Use and AMD Risk

  Ophthalmology

  GLP-1 Use and AMD Risk

  Barton Lynn Blackorby, MD; Katharine Talcott, MD

  • 

    

    Barton Lynn Blackorby, MD

  • 

    

    Katharine Talcott, MD

  • 

    

    Hong-Uyen Hua, MD

• 

  RestartResume

  MH Risk Factors After RRD Repair

  RestartResume

  MH Risk Factors After RRD Repair

  Ophthalmology

  MH Risk Factors After RRD Repair

  Maria H. Berrocal, MD; Avni P. Finn, MD, MBA

  • 

    

    Maria H. Berrocal, MD

  • 

    

    Avni P. Finn, MD, MBA

• 

  RestartResume

  Identifying Central and Branch Retinal Vein Occlusion

  RestartResume

  Identifying Central and Branch Retinal Vein Occlusion

  Eye on Ocular Health

  Identifying Central and Branch Retinal Vein Occlusion

  Jessica Randolph, MD

  • 

    

    Jessica Randolph, MD

• 

  RestartResume

  Retinal Vein Occlusion: The Case for Prompt Treatment

  RestartResume

  Retinal Vein Occlusion: The Case for Prompt Treatment

  Eye on Ocular Health

  Retinal Vein Occlusion: The Case for Prompt Treatment

  Ashkan Abbey, MD

  • 

    

    Ashkan Abbey, MD

• 

  RestartResume

  Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion

  RestartResume

  Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion

  Eye on Ocular Health

  Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion

  Ashkan Abbey, MD

  • 

    

    Ashkan Abbey, MD

• 

  RestartResume

  Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema

  RestartResume

  Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema

  Eye on Ocular Health

  Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema

• 

  RestartResume

  Examining Therapeutic Timing in RVO-Related Macular Edema

  RestartResume

  Examining Therapeutic Timing in RVO-Related Macular Edema

  Eye on Ocular Health

  Examining Therapeutic Timing in RVO-Related Macular Edema

• 

  RestartResume

  Outcomes for PDR Patients LTFU for at Least 1 Year

  RestartResume

  Outcomes for PDR Patients LTFU for at Least 1 Year

  Ophthalmology

  Outcomes for PDR Patients LTFU for at Least 1 Year

  Kyle Davis Kovacs, MD; Matt Starr, MD

  • 

    

    Kyle Davis Kovacs, MD

  • 

    

    Matt Starr, MD

  • 

    

    Nita Valikodath, MD, MS

• 

  RestartResume

  Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD

  RestartResume

  Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD

  Ophthalmology

  Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD

  Maria H. Berrocal, MD; Lejla Vajzovic, MD, FASRS

  • 

    

    Maria H. Berrocal, MD

  • 

    

    Lejla Vajzovic, MD, FASRS

• Prev
• 1
• 2
• 3
• 4
• 5
• Next